No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANIX Anixa Biosciences
- 2.270
- +0.050+2.25%
Close Jul 2 16:00 ET
72.65MMarket Cap-6135P/E (TTM)
2.310High2.160Low34.05KVolume2.220Open2.220Pre Close76.31KTurnover0.11%Turnover RatioLossP/E (Static)32.01MShares5.13052wk High3.08P/B69.08MFloat Cap2.14552wk Low--Dividend TTM30.43MShs Float8.950Historical High--Div YieldTTM6.75%Amplitude0.056Historical Low2.241Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Anixa Biosciences Treats Sixth Patient In Ongoing Phase 1 Clinical Trial Of Chimeric Antigen Receptor T-Cell Therapy For Ovarian Cancer
Anixa Biosciences Treats Sixth Patient in Its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Anixa Biosciences(ANIX.US) Director Buys US$10,720 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 4,000 shares of common stock on Jun 14, 2024 at an average price of $2.68 for a total value of $10,720.Source: Announcement What is
Anixa Biosciences(ANIX.US) Director Buys US$1,093.5 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 405 shares of common stock on Jun 13, 2024 at an average price of $2.7 for a total value of $1,093.5.Source: Announcement What is s
Anixa Biosciences(ANIX.US) Director Buys US$19,749.32 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 7,432 shares of common stock on Jun 10, 11, 2024 at an average price of $2.66 for a total value of $19,749.32.Source: Announcement
Anixa Biosciences(ANIX.US) Director Buys US$27,059.76 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 10,738 shares of common stock on Jun 7, 2024 at an average price of $2.52 for a total value of $27,059.76.Source: Announcement What
Comments
Anixa Biosciences: Current Developments and Future Prospects.
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences(ANIX.US$
https://stockregion.app/p/prominent-investment-bank-maintains
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences(ANIX.US$
https://stockregion.app/p/prominent-investment-bank-maintains
$Anixa Biosciences(ANIX.US$
NEWS
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targe...
NEWS
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targe...
$Anixa Biosciences(ANIX.US$
NEWS
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
NEWS
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg